Johannes Zakrzewski, M.D., is an Assistant Member of the Center for Discovery and Innovation.”
Specifically, Dr. Zakrzewski’s lab is investigating novel strategies for cancer immunotherapy and immunosurveillance by exploiting the endogenous capacity of the thymus to generate genetically modified T cells and harnessing advances in gene therapy and chimeric antigen receptor technology. They are also utilizing immunobioengineering methodologies to achieve thymus-independent T-cell generation. Finally, in collaboration with ImmuneTarget Inc., they are pursuing a drug development program aimed at improving the understanding of NF-κB and oxidative stress as therapeutic targets in multiple myeloma and other cancers. They recently entered the late preclinical stage of development of a novel small molecule inhibitor drug.